Normalization of mediotemporal and prefrontal activity, and mediotemporal-striatal connectivity, may underlie antipsychotic effects of cannabidiol in psychosis

Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial

(2018) Philip McGuire et al.   AMERICAN JOURNAL OF PSYCHIATRY

The anxiolytic effects of cannabidiol in chronically stressed mice are mediated by the endocannabinoid system: Role of neurogenesis and dendritic remodeling

(2018) Manoela V. Fogaça et al.   NEUROPHARMACOLOGY

Prefrontal GABA levels, hippocampal resting perfusion and the risk of psychosis

(2018) Gemma Modinos et al.   NEUROPSYCHOPHARMACOLOGY

Effect of Cannabidiol on Medial Temporal, Midbrain, and Striatal Dysfunction in People at Clinical High Risk of Psychosis

(2018) Sagnik Bhattacharyya et al.   JAMA Psychiatry

OUP accepted manuscript

(2017)   SCHIZOPHRENIA BULLETIN

Resting Hyperperfusion of the Hippocampus, Midbrain, and Basal Ganglia in People at High Risk for Psychosis

(2016) Paul Allen et al.   AMERICAN JOURNAL OF PSYCHIATRY

Cannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the Evidence

(2016) Cathrin Rohleder et al.   Frontiers in Pharmacology

Further human evidence for striatal dopamine release induced by administration of ∆9-tetrahydrocannabinol (THC): selectivity to limbic striatum

(2015) Matthijs G. Bossong et al.   PSYCHOPHARMACOLOGY

Hippocampal dysfunction during declarative memory encoding in schizophrenia and effects of genetic liability

(2015) Tara Pirnia et al.   SCHIZOPHRENIA RESEARCH

A systematic review of the antipsychotic properties of cannabidiol in humans

(2015) Tabitha A. Iseger et al.   SCHIZOPHRENIA RESEARCH

Functional and Neuroanatomic Specificity of Episodic Memory Dysfunction in Schizophrenia

(2015) J. Daniel Ragland et al.   JAMA Psychiatry

Imaging Patients with Psychosis and a Mouse Model Establishes a Spreading Pattern of Hippocampal Dysfunction and Implicates Glutamate as a Driver

(2013) Scott A. Schobel et al.   NEURON

Induction of Psychosis byΔ9-Tetrahydrocannabinol Reflects Modulation of Prefrontal and Striatal Function During Attentional Salience Processing

(2012) Sagnik Bhattacharyya   ARCHIVES OF GENERAL PSYCHIATRY

Improvement of Brain Reward Abnormalities by Antipsychotic Monotherapy in Schizophrenia

(2012) Mette Odegaard Nielsen et al.   ARCHIVES OF GENERAL PSYCHIATRY

Acute Effects of a Single, Oral dose of d9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) Administration in Healthy Volunteers

(2012) R. Martin-Santos et al.   CURRENT PHARMACEUTICAL DESIGN

Preliminary report of biological basis of sensitivity to the effects of cannabis on psychosis: AKT1 and DAT1 genotype modulates the effects of δ-9-tetrahydrocannabinol on midbrain and striatal function

(2012) S Bhattacharyya et al.   MOLECULAR PSYCHIATRY

Multimodal analysis of the hippocampus in schizophrenia using proton magnetic resonance spectroscopy and functional magnetic resonance imaging

(2012) Nathan L. Hutcheson et al.   SCHIZOPHRENIA RESEARCH

Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia

(2012) F M Leweke et al.   Translational Psychiatry

Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study

(2011) O Howes et al.   MOLECULAR PSYCHIATRY

Hippocampal dysregulation of dopamine system function and the pathophysiology of schizophrenia

(2011) Daniel J. Lodge et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Prefrontal Activation Deficits During Episodic Memory in Schizophrenia

(2009) John D. Ragland et al.   AMERICAN JOURNAL OF PSYCHIATRY

Modulation of Mediotemporal and Ventrostriatal Function in Humans by Δ9-Tetrahydrocannabinol

(2009) Sagnik Bhattacharyya et al.   ARCHIVES OF GENERAL PSYCHIATRY

Modulation of effective connectivity during emotional processing by Δ9-tetrahydrocannabinol and cannabidiol

(2009) Paolo Fusar-Poli et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Neurocognition in first-episode schizophrenia: A meta-analytic review.

(2009) Raquelle I. Mesholam-Gately et al.   NEUROPSYCHOLOGY

Opposite Effects of Δ-9-Tetrahydrocannabinol and Cannabidiol on Human Brain Function and Psychopathology

(2009) Sagnik Bhattacharyya et al.   NEUROPSYCHOPHARMACOLOGY

Changes in prefrontal and amygdala activity during olanzapine treatment in schizophrenia

(2009) Giuseppe Blasi et al.   PSYCHIATRY RESEARCH-NEUROIMAGING

Striatal Dopamine and Working Memory

(2008) S. M. Landau et al.   CEREBRAL CORTEX

The diverse CB1and CB2receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin

(2007) R G Pertwee   BRITISH JOURNAL OF PHARMACOLOGY